Better Buy: Johnson & Johnson vs. Eli Lilly
Pharmaceutical stocks have been hammered over the past year, leaving potential buyers with a plethora of potential bargains. At Johnson & Johnson , pharmaceutical sales have taken off, but consumer goods and medical devices still comprise the majority of its total revenue.
from Biotech News
0 Comments